Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.58 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022463 | 1.00 | ITGA4 (0.58) | ITGA4ITGB7KLK5MEN1KMT2A | |
| SCHEMBL4022466 | 1.00 | ITGA4 (0.58) | ITGA4ITGB7KLK5MEN1KMT2A | |
| SCHEMBL6428127 | 0.93 | ITGA4 (0.62) | ITGA4ITGB7KLK5ATMMAPT | |
| SCHEMBL7438704 | 0.90 | YAP1 (0.57) | ITGA4ITGB7MEN1KMT2AALDH1A1 | |
| SCHEMBL7438699 | 0.90 | YAP1 (0.57) | ITGA4ITGB7MEN1KMT2AALDH1A1 | |
| SCHEMBL6600210 | 0.90 | ITGA4 (0.53) | ITGA4ITGB7KLK5MEN1KMT2A | |
| SCHEMBL7439390 | 0.90 | ITGA4 (0.53) | ITGA4ITGB7KLK5MEN1KMT2A | |
| SCHEMBL7439396 | 0.90 | ITGA4 (0.53) | ITGA4ITGB7KLK5MEN1KMT2A | |
| SCHEMBL2476918 | 0.89 | ACE (0.54) | ITGA4ITGB7ATMMAPTTDP1 | |
| SCHEMBL3026223 | 0.89 | ACE (0.54) | ITGA4ITGB7ATMMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| EP-0858464-B1 | THROMBIN INHIBITORS | AKZO NOBEL NV (NL) | 2003-05-07 | — | — | EP | disclosed |
| US-20020142967-A1 | Thrombin inhibitors | ADANG A E P (NL) | 2002-10-03 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432921-B2 | OLIGOPEPTIDES | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-20010007764-A1 | THROMBIN INHIBITORS | N.V. ORGANON (NL) | 2001-07-12 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| EP-0956293-A1 | THROMBIN INHIBITORS | Akzo Nobel N.V. (NL) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| EP-0858464-A1 | THROMBIN INHIBITORS | Akzo Nobel N.V. (NL) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998007308-A2 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997017363-A1 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142967-A1 | Thrombin inhibitors | SERPINC1, DAO, CTRL | ITGA4 294/4885ITGB7 1376/4885KLK5 4593/4885 |
| US-20010007764-A1 | THROMBIN INHIBITORS | SERPINC1, DAO, F2 | ITGA4 587/4885ITGB7 514/4885KLK5 3825/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | ITGA4 785/4885ITGB7 838/4885KLK5 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.